Imunon (NASDAQ:IMNN) Given New $12.00 Price Target at HC Wainwright

Imunon (NASDAQ:IMNN) had its target price reduced by HC Wainwright from $14.00 to $12.00 in a research note released on Monday morning,Benzinga reports. They currently have a buy rating on the stock.

Separately, EF Hutton Acquisition Co. I raised Imunon to a “strong-buy” rating in a research report on Monday, September 23rd.

Imunon Stock Performance

Shares of IMNN stock opened at $0.83 on Monday. Imunon has a fifty-two week low of $0.48 and a fifty-two week high of $3.65. The firm has a market cap of $49.84 million, a P/E ratio of -0.44 and a beta of 2.14. The business’s 50 day moving average price is $1.01 and its 200-day moving average price is $1.19.

Imunon (NASDAQ:IMNN) last posted its earnings results on Wednesday, August 14th. The company reported ($0.51) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.55) by $0.04. As a group, equities analysts predict that Imunon will post -1.71 EPS for the current year.

Imunon Company Profile

Imunon, Inc, a clinical-stage biotechnology company, engages in the development of immunotherapies and vaccines to treat cancer and infectious diseases. The company’s lead clinical program IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development.